{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:54:10Z","timestamp":1762001650202},"reference-count":28,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2009,3,11]],"date-time":"2009-03-11T00:00:00Z","timestamp":1236729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2009,5]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold>Both genetic factors and environmental factors are suggested to play a role in the aetiology of inhibitor development in patients with severe haemophilia A. Monozygotic twins are ideal candidates to study the influence of environmental factors. We describe a pair of 3\u2010year\u2010old monozygotic twin brothers with severe haemophilia A. Prenatal diagnosis confirmed the presence of an intron 22 inversion. Other patient\u2010related factors such as birth weight, vaccinations and the duration of breastfeeding were similar. At the age of 7\u2003months, one boy suffered from a spontaneous subdural haematoma, which needed complete correction of haemostasis with continuous infusion of a third\u2010generation recombinant factor VIII. A persistent high\u2010titre inhibitor with severe clinical symptoms developed, that could only be eradicated with high\u2010dose immune tolerance induction (ITI) for 36\u2003months in combination with rituximab therapy. His twin brother first received treatment at 9\u2003months of age with the same FVIII product. After treatment on nine exposure days, he developed a low\u2010titre inhibitor at the age of 14.5\u2003months. Unlike his brother, he was tolerized without difficulties with low\u2010dose ITI within 2\u2003months. The discordant antibody responses were underlined by dissimilar IgG1 and IgG4 levels in their plasma. The discordant immune response to FVIII in this pair of monozygotic twin brothers seemed to be related to intensity of treatment and severity of bleeds. This confirms that these environmental factors play an additional role in the development of inhibitors.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2009.01998.x","type":"journal-article","created":{"date-parts":[[2009,3,12]],"date-time":"2009-03-12T01:32:26Z","timestamp":1236821546000},"page":"712-717","source":"Crossref","is-referenced-by-count":9,"title":["Discordant antibody response in monozygotic twins with severe haemophilia A caused by intensive treatment"],"prefix":"10.1111","volume":"15","author":[{"given":"S. C.","family":"GOUW","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. C.","family":"TER AVEST","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. M.","family":"VAN HELDEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"VOORBERG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. M.","family":"Van Den BERG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,4,21]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00780.x"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1351-8216.2001.00134.x"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1649954"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2001.00510.x"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3918"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-024711"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02290.x"},{"key":"e_1_2_7_9_2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1055\/s-0038-1655944","article-title":"HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party","volume":"77","author":"Hay CR","year":"1997","journal-title":"Thromb Haemost"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1655945"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1371"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-056291"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02828.x"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01418.x"},{"issue":"2","key":"e_1_2_7_15_2","first-page":"44","article-title":"A case control study to examine treatment related factors in the development of inhibitors in haemophilia A","volume":"14","author":"Maclean P","year":"2008","journal-title":"Haemophilia"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05605.x"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2000.00451.x"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/08880010500198764"},{"key":"e_1_2_7_19_2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1600-0609.1979.tb02856.x","article-title":"Development of factor VIII antibody in haemophilic monozygotic twins","volume":"23","author":"European Study Group of Factor VIII Antibody","year":"1979","journal-title":"Scand J Haematol"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1653759"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1651555"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613257"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07232.x"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.3.983.983"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1612943"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1159\/000056717"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.02127.x"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mbc.0000167660.30886.e9"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2005.01170.x"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2009.01998.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2009.01998.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T14:52:36Z","timestamp":1710168756000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2009.01998.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,21]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["10.1111\/j.1365-2516.2009.01998.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2009.01998.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,21]]}}}